Literature DB >> 11737790

Long-term outcome in 306 males with alcoholism.

T Noda1, H Imamichi, A Kawata, K Hirano, T Ando, Y Iwata, H Yoneda.   

Abstract

The subjects of this study were 306 male alcoholics who lived in Osaka, Japan, and who were initially diagnosed with alcoholism at a psychiatric institution between 1972 and 1983. Follow-up studies were done on three occasions: 1 March 1985 (Time 1), 1 November 1988 (Time 2) and 1 March 1992 (Time 3). We followed up 232 (75.8%) of the 306 male alcoholics. By the end of the study period 110 (35.9%) of the subjects were deceased. Regarding cross-sectional sobriety status, from Time 1 to Time 3 the complete abstinence rate changed from 16.0 to 18.6%, excessive drinking rate was from 13.1 to 9.8%, and controlled drinking rate was from 6.9 to 9.8%. The longitudinal sobriety status of 122 living patients during the 5 years before the close of this study were: rate of stable abstinence, 28.7%; unstable abstinence, 21.3%; controlled drinking, 12.3%; and relapse 37.7%. Such variables as being without public assistance at the time of the initial diagnosis of alcoholism and attending a self-help group soon after the initial treatment were associated with stable abstinence. Age (20-39 years) and receiving outpatient treatment at the time of the initial treatment also emerged as predictors of survival. However, those variables, except attending a self-help group soon after the initial treatment, might merely indicate severity of alcoholism. For improving treatment results, it may be most important to provide a treatment environment within the residential area so that alcoholics may receive treatment at an early stage of alcoholism and attend a self-help group.

Entities:  

Mesh:

Year:  2001        PMID: 11737790     DOI: 10.1046/j.1440-1819.2001.00909.x

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  7 in total

1.  Quality of life, alcohol detoxification and relapse: is quality of life a predictor of relapse or only a secondary outcome measure?

Authors:  Rocco Luigi Picci; Francesco Oliva; Marco Zuffranieri; Paola Vizzuso; Luca Ostacoli; Alessandro Jaretti Sodano; Pier Maria Furlan
Journal:  Qual Life Res       Date:  2014-06-15       Impact factor: 4.147

2.  Brain metabolite levels in recently sober individuals with alcohol use disorder: Relation to drinking variables and relapse.

Authors:  Natalie M Zahr; Rebecca A Carr; Torsten Rohlfing; Dirk Mayer; Edith V Sullivan; Ian M Colrain; Adolf Pfefferbaum
Journal:  Psychiatry Res Neuroimaging       Date:  2016-02-18       Impact factor: 2.376

3.  The 14-year course of alcoholism in a community sample: do men and women differ?

Authors:  Ellen L Edens; Anne L Glowinski; Kyle L Grazier; Kathleen K Bucholz
Journal:  Drug Alcohol Depend       Date:  2007-11-01       Impact factor: 4.492

4.  Impact of comorbid psychiatric disorders on the outcome of substance abusers: a six year prospective follow-up in two Norwegian counties.

Authors:  Anne Signe Landheim; Kjell Bakken; Per Vaglum
Journal:  BMC Psychiatry       Date:  2006-10-20       Impact factor: 3.630

5.  Nalmefene in alcohol-dependent patients with a high drinking risk: Randomized controlled trial.

Authors:  Hisatsugu Miyata; Masayoshi Takahashi; Yoshiyuki Murai; Kana Tsuneyoshi; Takako Hayashi; Didier Meulien; Per Sørensen; Susumu Higuchi
Journal:  Psychiatry Clin Neurosci       Date:  2019-08-05       Impact factor: 5.188

6.  Long-term safety and efficacy of nalmefene in Japanese patients with alcohol dependence.

Authors:  Susumu Higuchi; Masayoshi Takahashi; Yoshiyuki Murai; Kana Tsuneyoshi; Izuru Nakamura; Didier Meulien; Hisatsugu Miyata
Journal:  Psychiatry Clin Neurosci       Date:  2020-05-27       Impact factor: 5.188

7.  An ongoing process: a qualitative study of how the alcohol-dependent free themselves of addiction through progressive abstinence.

Authors:  Mei-Yu Yeh; Hui-Lian Che; Shu-Mei Wu
Journal:  BMC Psychiatry       Date:  2009-11-24       Impact factor: 3.630

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.